[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Reproductive Medicine Associates of New Jersey\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,38,62,94,115,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100583744","male-infertility-and-assisted-reproductive-technologies-research-biobank-100583744",false,"NCT06880302","Male Infertility and Assisted Reproductive Technologies Research Biobank","MARK","Inclusion Criteria:\n\n* Males providing testicular tissue, sperm, semen samples, discarded sperm preps for IUI\u002FIVF\u002FICSI or the sperm recipient for those utilizing donor sperm, for cryopreservation at the respective site(s) for either clinical use or preservation\n\nExclusion Criteria:\n\n* Samples that are quarantined or in isolation dewars for infectious diseases","MALE",{"count":18,"type":19},1000,"ESTIMATED","OBSERVATIONAL","The objective of this research is to build a biobank of biological male specimens used for diagnostics and treatment of infertility or assisted reproductive technologies (ART).",[23,24],"Male Infertility","Infertility (IVF Patients)","RECRUITING","2026-06-01",{"date":28,"type":29},"2026-06-02","ACTUAL",{"date":31,"type":29},"2025-03-04",{"date":33,"type":19},"2032-12",{"name":35,"class":36},"Reproductive Medicine Associates of New Jersey","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":37},"100578829","quantifying-uterine-elastography-in-menstruating-women-100578829","NCT06816381","Quantifying Uterine Elastography in Menstruating Women","Characterizing Uterine and Ovarian Tissue Stiffness Via Shear Wave Elastography in Non-Infertile, Fertile, and Infertile Women With Normal Anatomy Across the Menstrual Cycle: A Pilot Study","QUEST","Group A\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28-34 days\n* Patients with normal uterine anatomy\n* Patients with no prior pregnancy history including miscarriages, terminations, ectopic pregnancies, preterm deliveries, or full-term deliveries\n* Patient who have no known infertility (i.e. women who have not tried to conceive)\n\nExclusion Criteria:\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of -endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.\n\nGroup B\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28 days to 34 days.\n* Patients with normal uterine and ovarian anatomy (absence of gross pathology on screening visit ultrasound)\n* Patients with at least one prior full-term vaginal delivery with time to conception less than one year without the use of assisted reproductive technology.\n\nExclusion Criteria\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of cesarean section\n* Patient who have no known secondary infertility (i.e. women who have not tried to conceive)\n* Diagnosis of secondary infertility (i.e women who have attempted pregnancy for 12 months without success)\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.\n\nGroup C\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28 days to 34 days.\n* Patients with normal uterine and ovarian anatomy (absence of gross pathology on screening visit ultrasound)\n* Patient with no prior pregnancy history including miscarriages, terminations, ectopic pregnancies, preterm deliveries, or full-term deliveries (i.e gravity equals zero).\n* Patient with diagnosis of primary infertility, with attempted conception for at least 12 months if younger than 35 years and attempted conception for at least 6 months if 35 years or older.\n\nExclusion Criteria\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of three or more failed euploid embryo transfers\n* Severe male factor infertility including severe oligozoospermia and cryptozoospermia\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.",true,"FEMALE","18 Years","45 Years",{"count":51,"type":19},40,"This study is aiming to characterize the elasticity of the female reproductive tract including the uterus, cervix and ovary using shear wave elastography at different times during the menstrual cycle and define the standard reference range of normal uterine and ovarian elasticity. By doing so, the potential of using shear wave elastography to diagnose and predict outcomes for patients seeking fertility treatment might be established.",[24,54],"Infertility Assisted Reproductive Technology",{"date":56,"type":29},"2026-06-03",{"date":58,"type":29},"2025-02-06",{"date":60,"type":19},"2027-12",{"name":35,"class":36},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":37},"100564483","the-epic-study-exploring-paternal-age-and-the-influence-on-blastocyst-culture-100564483","NCT06629766","The EPIC Study: Exploring Paternal Age and the Influence on Blastocyst Culture","EPIC","Inclusion Criteria:\n\n* Undergoing first IVF cycle\n* Electing single embryo transfer\n* Electing PGT-A of their embryos\n* Female partners age \\\u003C42 years old at start of VOR cycle, but \\>18 years old.\n* AMH ≥ 1.2 ng\u002FmL\n* AFC ≥ 8\n* FSH ≤ 12IU\u002FL\n* At least 4 mature oocytes (M2s) retrieved at the VOR procedure in order to randomize\n* Intention to transfer the morphological best quality, euploid, embryo at the frozen embryo transfer procedure\n\nExclusion Criteria:\n\n* Contraindication to IVF\n* Clinical indication for preimplantation genetic testing (i.e., screening for single gene disorder, chromosomal translocation, or any other disorders requiring a more detailed embryo genetic analysis)\n* Male partner with azoospermia or oligozoospermia (\\\u003C500,000 total motile spermatozoa on the most recent semen analysis within one year of enrollment)\n* Planned for previously cryopreserved sperm to be used for ICSI\n* Donor sperm\n* Male partner with Y-chromosome microdeletion\n* Male partner with any Karyotype other than 46,XY\n* Male partner requiring surgically obtained sperm either via testicular or epididymal retrieval procedures\n* Uncorrected hydrosalpinges that communicate with the endometrial cavity\n* Endometrial Insufficiency, as defined by a prior cycle with maximal endometrial thickness \\\u003C6mm,), or persistent endometrial fluid\n* Donor oocyte or embryo cycles\n* Gestational carriers","41 Years",{"count":71,"type":19},100,"INTERVENTIONAL",[74],"NA","This study aims to assess the effect of age of the male partner and the reproductive ability of sperm prepared via sperm selection devices (Zymot) compared to routine embryologist selected sperm after density gradient centrifugation (DGC) preparation for intracytoplasmic sperm injection (ICSI) in patients undergoing in vitro fertilization treatment (IVF) of their infertility.",[24,77,78,79,80],"Oocyte Competence","Sperm DNA Fragmentation","Paternal Age","Sperm Selection",[82,83,84,85,86,87],"microfluidic","density grade centrifugation","sperm selection","paternal age","sperm DNA fragmentation","Zymot",{"date":56,"type":29},{"date":90,"type":29},"2025-04-09",{"date":92,"type":19},"2028-12",{"name":35,"class":36},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":72,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":37},"100545132","investigating-micro-manipulation-procedures-for-assisted-hatching-timing-100545132","NCT06377917","Investigating Micro-Manipulation Procedures for Assisted Hatching Timing","The IMPACT Trial: Investigating Micro-Manipulation Procedures for Assisted Hatching Timing","IMPACT","Inclusion Criteria for participants:\n\n1. Patients undergoing an IVF cycle with plan for subsequent FET of a single euploid embryo\n2. \\\u003C4 2PNs prior to randomization\n3. Female partners age \\\u003C42 years old at start of VOR cycle\n4. Normal ovarian reserve:\n\n   1. AMH ≥ 1.2 ng\u002FmL\n   2. AFC ≥ 8\n   3. FSH ≤ 12IU\u002FL\n5. BMI \\\u003C38\n6. Patients who desire to transfer the best quality embryo for their embryo transfer.\n\nExclusion Criteria for participants:\n\n1. All patients who do not voluntarily give their written consent for participation\n2. Patients with a prior failed IVF cycle - defined as no blastocysts\n3. Patients with a history of more than one failed euploid embryo transfer\n4. Donor oocyte cycles\n5. Gestational Carriers\n6. Male partner with \\\u003C100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)\n7. Use of surgical procedures to obtain sperm\n8. Communicating hydrosalpinges without a plan for surgical correct prior to frozen embryo transfer\n9. Endometrial Insufficiency, as defined by a prior cycle with maximal endometrial thickness \\\u003C6mm,), or persistent endometrial fluid\n10. Single gene disorders, chromosomal translocations, or any other disorders requiring a more detailed embryo genetic analysis than standard PGT-A","42 Years",{"count":104,"type":19},75,[74],"This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility.",[108],"Infertility",{"date":56,"type":29},{"date":111,"type":29},"2026-05-31",{"date":113,"type":19},"2028-05-31",{"name":35,"class":36},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":123,"targetDuration":4,"studyType":72,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":133,"locationsCount":37},"100480619","platelet-rich-plasma-for-insufficient-endometrium-100480619","NCT05538338","Platelet Rich Plasma for Insufficient Endometrium","Intrauterine Platelet Rich Plasma (PRP) Infusion for Endometrial Insufficiency: A Prospective, Double-Blind, Placebo-Controlled Randomized Controlled Trial","PIER","Inclusion Criteria:\n\n* Patients who have previously undergone at least 2 unsuccessful frozen embryo transfer cycles, defined as failure to achieve a sustained clinical pregnancy (visualization of intrauterine gestational sac on ultrasound or a cancelled embryo transfer cycle due to inadequate endometrial thickness\n* Patients with a diagnosis of thin endometrial lining (less than or equal to 6 mm maximum thickness) during prior unsuccessful or canceled embryo transfer cycles.\n\nExclusion Criteria:\n\n* Fewer than 2 prior unsuccessful or canceled frozen embryo transfer cycles.\n* Most recent unsuccessful embryo transfer prior to January 1, 2017.\n* Mullerian anomalies, excluding arcuate uterus\n* Concurrent submucosal fibroids, unrepaired uterine defects or present indication for uterine surgery\n* Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.\n* Failure of patient to agree to enrollment in study with written consent.\n* Concurrent pregnancy\n* Anticoagulation use for which plasma infusion is contraindicated\n* History of thrombosis\n* Thrombophilia either inherited or acquired\n* Concomitant use of adjunctive therapies for proliferation. These must be discontinued upon enrollment.\n* Embryo planned to be used for transfer generated from surgically obtained sperm due to a diagnosis of non-obstructive azoospermia\n* Recurrent\u002Fpersistent endometrial fluid in prior cycles",{"count":124,"type":19},62,[74],"To determine the effectiveness of an intrauterine PRP infusion on endometrial thickness and in vitro fertilization (IVF) outcomes in a population of infertile women with a history of unresponsive thin endometrium.",[128],"Infertility of Uterine Origin",{"date":56,"type":29},{"date":131,"type":29},"2022-10-15",{"date":60,"type":19},{"name":35,"class":36},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":46,"sex":141,"minAge":48,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":37},"100149633","discarded-materials-study-100149633","NCT01219335","Discarded Materials Study","Laboratory Evaluation of De-identified, Developmentally Arrested Embryos of Embryos Diagnosed as Having an Abnormal Number of Chromosomes for Optimization of Techniques for Assisted Reproduction","Inclusion Criteria:\n\nnone\n\nExclusion Criteria:\n\nnone","ALL","65 Years",{"count":144,"type":19},10000,"Use of discarded embryos to advance laboratory expertise and technology in the area of human embryo development and assisted reproductive technologies",[108],[148],"IVF",{"date":56,"type":29},{"date":151,"type":4},"2003-04",{"date":153,"type":19},"2029-12",{"name":35,"class":36},""]